Pentoxifylline/NN
for/IN
the/DT
treatment/NN
of/IN
infection/NN
with/IN
human/JJ
immunodeficiency/NN
virus/NN
./.

Cytokine/NN
dysregulation/NN
in/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
infection/NN
has/VBZ
been/VBN
documented/VBN
in/IN
numerous/JJ
studies/NNS
and/CC
has/VBZ
been/VBN
cited/VBN
as/IN
an/DT
important/JJ
component/NN
in/IN
the/DT
pathogenesis/NN
of/IN
this/DT
retroviral/JJ
infection/NN
./.
=====
Pharmacological/JJ
modification/NN
of/IN
cytokine/NN
dysregulation/NN
,/,
therefore/RB
,/,
has/VBZ
been/VBN
suggested/VBN
as/IN
a/DT
therapeutic/JJ
modality/NN
for/IN
HIV-1/NN
infection/NN
./.
=====
Dr./NNP
Dezube/NNP
of/IN
Beth/NNP
Israel/NNP
Hospital/NNP
(/(
Boston/NNP
)/)
concisely/RB
reviews/VBZ
the/DT
state/NN
of/IN
our/PRP$
knowledge/NN
regarding/VBG
the/DT
effects/NNS
of/IN
pentoxifylline/NN
on/IN
expression/NN
of/IN
tumor/NN
necrosis/NN
factor-alpha/NN
,/,
a/DT
cytokine/NN
known/VBN
to/TO
influence/VB
HIV-1/NN
replication/NN
and/CC
to/TO
play/VB
a/DT
possible/JJ
role/NN
in/IN
the/DT
clinical/JJ
manifestations/NNS
of/IN
advanced/JJ
infection/NN
with/IN
this/DT
virus/NN
./.
=====
Pentoxifylline/NN
,/,
a/DT
trisubstituted/JJ
xanthine/NN
derivative/NN
,/,
has/VBZ
been/VBN
used/VBN
to/TO
decrease/VB
blood/NN
viscosity/NN
and/CC
is/VBZ
reasonably/RB
well/RB
tolerated/VBN
by/IN
most/JJS
recipients/NNS
of/IN
the/DT
drug/NN
./.
=====
Results/NNS
of/IN
preliminary/JJ
studies/NNS
,/,
many/JJ
of/IN
which/WDT
were/VBD
conducted/VBN
by/IN
Dr./NNP
Dezube/NNP
,/,
suggest/VBP
that/IN
use/NN
of/IN
this/DT
agent/NN
in/IN
combination/NN
with/IN
antiretroviral/JJ
compounds/NNS
may/MD
prove/VB
useful/JJ
in/IN
the/DT
treatment/NN
of/IN
patients/NNS
with/IN
HIV-1/NN
infection/NN
./.